Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

Ibrutinib has significantly improved the outcome of patients with relapsed chronic lymphocytic leukemia (CLL). Recent reports attribute ibrutinib resistance to acquired mutations in Bruton agammaglobulinemia tyrosine kinase (BTK), the target of ibrutinib, as well as the immediate downstream effector...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood
Autores principales: Liu, Ta-Ming, Woyach, Jennifer A., Zhong, Yiming, Lozanski, Arletta, Lozanski, Gerard, Dong, Shuai, Strattan, Ethan, Lehman, Amy, Zhang, Xiaoli, Jones, Jeffrey A., Flynn, Joseph, Andritsos, Leslie A., Maddocks, Kami, Jaglowski, Samantha M., Blum, Kristie A., Byrd, John C., Dubovsky, Jason A., Johnson, Amy J.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2015
Materias:
Lymphoid Neoplasia
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4492196/
https://ncbi.nlm.nih.gov/pubmed/25972157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-02-626846
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares